#USA #Nashville #Stroke Recovery #Phagenesis #Dysphagia

Pharyngeal Electrical Stimulation: A Game-Changer in Post-Stroke Recovery

In a significant advancement for rehabilitation in stroke patients, the American Heart Association (AHA) and the American Stroke Association (ASA) have officially recognized pharyngeal electrical stimulation (PES) as a crucial component in the management of dysphagia, a common condition following a stroke. This new recommendation is expected to transform recovery protocols by providing validated therapeutic options that enhance swallowing control.

Understanding Dysphagia Post-Stroke

Dysphagia, or difficulty swallowing, affects approximately 45% of stroke survivors. This condition not only poses a challenge to basic functions such as eating and drinking, but also leads to severe complications, including aspiration pneumonia and increased hospital readmission rates. Furthermore, evidence suggests that patients suffering from dysphagia post-stroke have a staggering eight times higher risk of mortality within three months of onset. Given these alarming statistics, the inclusion of PES in clinical guidelines offers hope for better recovery trajectories.

The Role of PES in Stroke Rehabilitation

Phagenesis, the pioneering company behind the development of the Phagenyx System, has introduced a neuromodulation therapy that utilizes PES to target the sensory nerves in the throat, hence restoring the brain's ability to manage swallowing functions. What sets Phagenyx apart is its clinical validation; backed by over 30 peer-reviewed studies, including randomized controlled trials, PES has been shown to significantly enhance swallowing safety and reduce the severity of dysphagia.

Dr. H. Alex Choi, a leading figure in neurology and neurosurgery at The University of Texas Health Science Center, expresses the potential of PES: "Despite the historical lack of effective interventions, we now have a validated tool that can significantly improve the quality of life for patients by restoring their ability to eat and drink. Dysphagia should be seen not just as a hurdle for hospital discharge but as a therapeutic target instead."

Current Clinical Guidelines and Recommendations

The AHA/ASA's new clinical practice guidelines outline specific recommendations regarding the application of PES:

• - For patients with dysphagia post-stroke: PES can be beneficial in reducing dysphagia severity and minimizing the risk of aspiration.
• - For severe cases requiring tracheotomy and mechanical ventilation: PES has demonstrated effectiveness after ventilator weaning, facilitating faster recovery from dysphagia symptoms.

These therapeutics are classified as Class of Recommendation 2a, with a Level of Evidence B-R, indicating encouraging results from available studies that support PES's efficacy and safety in clinical practice.

Impact on Patient Care and Recovery

The recognition of PES as a valuable addition to stroke recovery protocols is not just a boost for healthcare providers but also instills hope in patients and their families. The ability to restore essential functions significantly impacts a patient’s mental well-being and overall quality of life. Furthermore, with PES integrated into routine stroke care, clinicians have a powerful tool at their disposal aimed at reducing complications associated with dysphagia, thus alleviating concerns surrounding long-term care dependencies and improving recovery outcomes.

Chad Hoskins, CEO of Phagenesis, reiterates the significance of this advancement: "The formal inclusion of PES in AHA guidelines reinforces our mission to improve outcomes for stroke survivors while also streamlining care processes for healthcare providers. Our years of research and collaboration with clinical partners emphasize the importance of addressing dysphagia effectively."

Looking Forward

As the medical community embraces the implications of this new guideline, patients coping with the aftermath of strokes can look forward to comprehensive rehabilitation strategies tailored to their needs. The continued development of therapies like Phagenyx reiterates the commitment to innovative solutions in medical technology, enabling stroke survivors to reclaim their independence through restored swallowing capabilities.

For more information and resources, visit Phagenesis.

Conclusion

The inclusion of pharyngeal electrical stimulation in the AHA/ASA guidelines marks a pivotal shift in the treatment of post-stroke complications. As healthcare providers incorporate these recommendations, patients stand to benefit from improved therapy options, emphasizing the need for ongoing research and innovation in the field of stroke recovery.